EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report

por Diem, Stefan, Früh, Martin, Rodriguez, Regulo, Liechti, Peter, Rothermundt, Christian
Publicado 2013

Accelerated Course of Alveolar Echinococcosis After Treatment With Steroids in a Patient With Autoimmune Encephalitis

por Diem, Stefan, Gottstein, Bruno, Beldi, Guido, Semmo, Nasser, Diem, Lara F
Publicado 2021

Mycophenolate mofetil as second line treatment in autoimmune hepatitis – A retrospective single center analysis

por Kolev, Mirjam, Diem, Stefan, Diem, Lara, Rodrigues, Susana G., Berzigotti, Annalisa, Stirnimann, Guido, Semmo, Nasser
Publicado 2022

GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography

por Hasan Ali, Omar, Diem, Stefan, Aschwanden, Josef, Markert, Eva, Tasman, Abel-Jan, Mueller, Joachim, Flatz, Lukas
Publicado 2016

Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma

por Favara, David M, Spain, Lavinia, Au, Lewis, Clark, James, Daniels, Ella, Diem, Stefan, Chauhan, Dharmisha, Turajlic, Samra, Powell, Nick, Larkin, James M, Yousaf, Nadia
Publicado 2020

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment

por Diem, Stefan, Fässler, Mirjam, Hasan Ali, Omar, Siano, Marco, Niederer, Rebekka, Berner, Fiamma, Roux, Guillaume-Alexandre, Ackermann, Christoph Jakob, Schmid, Sabine, Güsewell, Sabine, Früh, Martin, Flatz, Lukas
Publicado 2018

Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs

por Herbrand, Amanda Katherina, Schmitt, Andreas M., Briel, Matthias, Ewald, Hannah, Goldkuhle, Marius, Diem, Stefan, Hoogkamer, Anouk, Joerger, Markus, Moffa, Giusi, Novak, Urban, Hemkens, Lars G., Kasenda, Benjamin
Publicado 2021

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients

por Hasan Ali, Omar, Berner, Fiamma, Ackermann, Christoph Jakob, Ring, Sandra Stephanie, Moulin, Alexandre, Müller, Joachim, Markert, Eva, Pop, Oltin Tiberiu, Müller, Stefanie, Diem, Stefan, Hundsberger, Thomas, Flatz, Lukas
Publicado 2020

Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

por Herbrand, Amanda Katherina, Schmitt, Andreas Michael, Briel, Matthias, Diem, Stefan, Ewald, Hannah, Hoogkamer, Anouk, Joerger, Markus, Mc Cord, Kimberly Alba, Novak, Urban, Sricharoenchai, Sirintip, Hemkens, Lars G, Kasenda, Benjamin
Publicado 2019

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

por Klümper, Niklas, Saal, Jonas, Berner, Fiamma, Lichtensteiger, Christa, Wyss, Nina, Heine, Annkristin, Bauernfeind, Franz Georg, Ellinger, Jörg, Brossart, Peter, Diem, Stefan, Schmid, Sabine, Joerger, Markus, Frueh, Martin, Ritter, Manuel, Hölzel, Michael, Flatz, Lukas, Bald, Tobias
Publicado 2022

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients

por Purde, Mette-Triin, Niederer, Rebekka, Wagner, Nikolaus B., Diem, Stefan, Berner, Fiamma, Hasan Ali, Omar, Hillmann, Dorothea, Bergamin, Irina, Joerger, Markus, Risch, Martin, Niederhauser, Christoph, Lenz, Tobias L., Früh, Martin, Risch, Lorenz, Semela, David, Flatz, Lukas
Publicado 2021

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

por Bowyer, Samantha, Prithviraj, Prashanth, Lorigan, Paul, Larkin, James, McArthur, Grant, Atkinson, Victoria, Millward, Michael, Khou, Muoi, Diem, Stefan, Ramanujam, Sangeetha, Kong, Ben, Liniker, Elizabeth, Guminski, Alexander, Parente, Phillip, Andrews, Miles C, Parakh, Sagun, Cebon, Jonathan, Long, Georgina V, Carlino, Matteo S, Klein, Oliver
Publicado 2017

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

por Fässler, Mirjam, Diem, Stefan, Mangana, Joanna, Hasan Ali, Omar, Berner, Fiamma, Bomze, David, Ring, Sandra, Niederer, Rebekka, del Carmen Gil Cruz, Cristina, Pérez Shibayama, Christian Ivan, Krolik, Michal, Siano, Marco, Joerger, Markus, Recher, Mike, Risch, Lorenz, Güsewell, Sabine, Risch, Martin, Speiser, Daniel E., Ludewig, Burkhard, Levesque, Mitchell P., Dummer, Reinhard, Flatz, Lukas
Publicado 2019

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

por Wagner, Nikolaus B, Lenders, Max M, Kühl, Kathrin, Reinhardt, Lydia, André, Fiona, Dudda, Milena, Ring, Natalie, Ebel, Chiara, Stäger, Ramon, Zellweger, Caroline, Lang, Roland, Paar, Michael, Gussek, Philipp, Richtig, Georg, Stürmer, Suzan H, Kimeswenger, Susanne, Oellinger, Angela, Forschner, Andrea, Leiter, Ulrike, Weide, Benjamin, Gassenmaier, Maximilian, Schraag, Amadeus, Klumpp, Bernhard, Hoetzenecker, Wolfram, Berking, Carola, Richtig, Erika, Ziemer, Mirjana, Mangana, Johanna, Terheyden, Patrick, Loquai, Carmen, Nguyen, Van Anh, Gebhardt, Christoffer, Meier, Friedegund, Diem, Stefan, Cozzio, Antonio, Flatz, Lukas, Röcken, Martin, Garbe, Claus, Eigentler, Thomas K
Publicado 2021